Bank of America
EIGR

Bank of America’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Bank of America’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,174
Closed -$5.88K – 8570
2024
Q1 		$5.88K Sell
1,174
-430
-27% -$2.67K ﹤0.01% 6978
2023
Q4 		$10.8K Sell
1,604
-73
-4% -$642 ﹤0.01% 6900
2023
Q3 		$15.3K Sell
1,677
-4
-0.2% -$80 ﹤0.01% 6764
2023
Q2 		$35.5K Sell
1,681
-231
-12% -$7.12K ﹤0.01% 6563
2023
Q1 		$51.4K Buy
1,912
+359
+23% +$16.7K ﹤0.01% 6499
2022
Q4 		$55K Buy
1,553
+1,103
+245% +$133K ﹤0.01% 6449
2022
Q3 		$103K Sell
450
-157
-26% -$38.6K ﹤0.01% 6337
2022
Q2 		$115K Sell
607
-143
-19% -$28.8K ﹤0.01% 6402
2022
Q1 		$187K Sell
750
-269
-26% -$42.5K ﹤0.01% 6508
2021
Q4 		$159K Buy
1,019
+389
+62% +$75.2K ﹤0.01% 6627
2021
Q3 		$126K Sell
630
-71
-10% -$16.9K ﹤0.01% 6592
2021
Q2 		$180K Sell
701
-10
-1% -$2.5K ﹤0.01% 6163
2021
Q1 		$189K Sell
711
-1,290
-64% -$406K ﹤0.01% 6085
2020
Q4 		$738K Sell
2,001
-69
-3% -$19.8K ﹤0.01% 4734
2020
Q3 		$505K Sell
2,070
-116
-5% -$36.1K ﹤0.01% 4706
2020
Q2 		$630K Sell
2,186
-114
-5% -$33.6K ﹤0.01% 4458
2020
Q1 		$469K Buy
2,300
+823
+56% +$262K ﹤0.01% 4540
2019
Q4 		$660K Buy
1,477
+462
+46% +$164K ﹤0.01% 4812
2019
Q3 		$312K Buy
1,015
+117
+13% +$38K ﹤0.01% 5392
2019
Q2 		$286K Sell
898
-138
-13% -$47.8K ﹤0.01% 5436
2019
Q1 		$435K Buy
1,036
+173
+20% +$69.4K ﹤0.01% 5100
2018
Q4 		$263K Buy
863
+286
+50% +$92.4K ﹤0.01% 5345
2018
Q3 		$208K Buy
577
+47
+9% +$16.1K ﹤0.01% 5465
2018
Q2 		$194K Sell
530
-77
-13% -$27.4K ﹤0.01% 5431
2018
Q1 		$180K Buy
607
+507
+507% +$150K ﹤0.01% 5427
2017
Q4 		$42K Sell
100
-3
-3% -$1.07K ﹤0.01% 6146
2017
Q3 		$34K Sell
103
-40
-28% -$10.9K ﹤0.01% 6102
2017
Q2 		$34K Buy
143
+118
+472% +$26.8K ﹤0.01% 6038
2017
Q1 		$8K Buy
25
+6
+32% +$2.07K ﹤0.01% 6596
2016
Q4 		$7K Buy
19
+5
+36% +$1.83K ﹤0.01% 6642
2016
Q3 		$6K Buy
14
+12
+600% +$6.12K ﹤0.01% 6561
2016
Q2 		$1K Buy
2
+1
+100% +$607 ﹤0.01% 7020
2016
Q1 		$0 Sell
1
-6
-86% -$2.99K ﹤0.01% 7403
2015
Q4 		$5K Buy
+7
New +$3.96K ﹤0.01% 6891
2015
Q3 		– Hold
0
– – – 7468
2015
Q2 		– Hold
0
– – – 7461
2015
Q1 		– Sell
-2
Closed -$17.5K – 6877
2014
Q4 		$18K Buy
+2
New +$11.6K ﹤0.01% 6843
2014
Q3 		– Sell
-57
Closed -$301K – 7906
2014
Q2 		$409K Buy
57
+55
+2,750% +$275K ﹤0.01% 4825
2014
Q1 		$12K Buy
+2
New +$9.45K ﹤0.01% 7140

Other funds holding EIGR

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America's EIGR Position: Q2 2024 in Review

Bank of America sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 1,174 shares — an estimated $5.88K sold.

Bank of America first reported a position in EIGR in Q1 2014 and held it in 37 quarters. The position peaked at $738K in Q4 2020. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

  • Bank of America reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Bank of America sold 1,174 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $5.88K.
  • Bank of America first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 37 quarters.
  • Bank of America's Eiger BioPharmaceuticals, Inc. position peaked at $738K in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on Bank of America's 13F filing for Q2 2024, filed 14 Aug 2024.